Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06083922 · ClinicalTrials.gov registry record · Phase 2

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

A Phase 2 study of Multiple Myeloma and Monoclonal Gammopathy of Renal Significance, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
11
Study locations

NCT06083922: Recruiting Phase 2 study of Multiple Myeloma and Monoclonal Gammopathy of Renal Significance, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06083922 is a Phase 2 study of Multiple Myeloma and Monoclonal Gammopathy of Renal Significance that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06083922, a Phase 2 study of Multiple Myeloma and Monoclonal Gammopathy of Renal Significance, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.

Primary Outcome

Any participant in the run-in-phase who received at least ≥ 75% of the planned doses of the combination regimen in cycle one will be evaluated for DLTs using NCI-CTCAE.

Conditions Studied

Multiple Myeloma Monoclonal Gammopathy of Renal Significance

Interventions

  • DRUG Cyclophosphamide
  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Bortezomib

Study Locations (11)

New York

  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Weill Cornell Medical Center (Data Collection Only) - New York
  • Mount Sinai Hospital (Data Collection Only) - New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Massachusetts

  • Tufts Medical Center (Data Collection Only) - Boston

North Carolina

  • University of North Carolina (Data Collection Only) - Chapel Hill

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-10-16
Est. Completion 2026-10
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT06083922 shows while recruiting

NCT06083922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT06083922 lists 11 locations in 4 states (New York, New Jersey, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT06083922 about?

NCT06083922 is a clinical study titled "A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)". The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether...

What is the current status of trial NCT06083922?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-10-16. Estimated completion is 2026-10.

What conditions does trial NCT06083922 study?

This clinical trial studies the following conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance.

What interventions are being tested in trial NCT06083922?

The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT06083922?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06083922 being conducted?

This trial has 11 study locations across Massachusetts, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06083922's enrollment target sits among peer trials

20 381st of 438 higher than 47 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06083922

Source: ClinicalTrials.gov NCT06083922, the US trial registry maintained by the National Library of Medicine. NCT06083922 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.